10x Genomics, Inc. TXG
We take great care to ensure that the data presented and summarized in this overview for 10x Genomics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TXG
View all-
Vanguard Group Inc Valley Forge, PA10.2MShares$219 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl9.31MShares$201 Million1.65% of portfolio
-
Black Rock Inc. New York, NY6.39MShares$138 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.6.15MShares$132 Million1.4% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.6.14MShares$132 Million0.09% of portfolio
-
Morgan Stanley New York, NY5.77MShares$124 Million0.01% of portfolio
-
Generation Investment Management LLP London, X02.88MShares$62.1 Million0.28% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.87MShares$61.9 Million0.01% of portfolio
-
Baillie Gifford & CO2.74MShares$59.1 Million0.04% of portfolio
-
Brown Capital Management LLC Baltimore, MD2.48MShares$53.5 Million0.99% of portfolio
Latest Institutional Activity in TXG
Top Purchases
Top Sells
About TXG
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Insider Transactions at TXG
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 30
2024
|
Sarah A. Teichmann |
BUY
Grant, award, or other acquisition
|
Direct |
19,002
+50.0%
|
-
|
Aug 22
2024
|
Serge Saxonov Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
6,749
-0.76%
|
$148,478
$22.53 P/Share
|
Aug 22
2024
|
Justin J. Mc Anear |
SELL
Open market or private sale
|
Direct |
2,961
-2.03%
|
$65,142
$22.53 P/Share
|
Aug 22
2024
|
Benjamin J. Hindson |
SELL
Open market or private sale
|
Direct |
4,351
-1.24%
|
$95,722
$22.53 P/Share
|
Jul 31
2024
|
Alan Mateo |
BUY
Grant, award, or other acquisition
|
Direct |
21,691
+50.0%
|
-
|
Jun 11
2024
|
Sridhar Kosaraju |
BUY
Grant, award, or other acquisition
|
Direct |
8,649
+17.39%
|
-
|
Jun 11
2024
|
John R Stuelpnagel |
BUY
Grant, award, or other acquisition
|
Direct |
8,649
+2.45%
|
-
|
Jun 11
2024
|
Mathai Mammen |
BUY
Grant, award, or other acquisition
|
Direct |
8,649
+4.58%
|
-
|
Jun 11
2024
|
Shehnaaz Suliman |
BUY
Grant, award, or other acquisition
|
Direct |
8,649
+39.48%
|
-
|
Jun 11
2024
|
Kimberly J Popovits |
BUY
Grant, award, or other acquisition
|
Direct |
8,649
+39.48%
|
-
|
May 29
2024
|
Serge Saxonov Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
425
-0.05%
|
-
|
May 22
2024
|
Benjamin J. Hindson |
SELL
Open market or private sale
|
Direct |
4,087
-1.15%
|
$98,088
$24.3 P/Share
|
May 22
2024
|
Serge Saxonov Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,877
-0.55%
|
$117,048
$24.3 P/Share
|
May 22
2024
|
Justin J. Mc Anear |
SELL
Open market or private sale
|
Direct |
2,936
-1.97%
|
$70,464
$24.3 P/Share
|
Mar 21
2024
|
Justin J. Mc Anear |
BUY
Grant, award, or other acquisition
|
Direct |
53,312
+26.41%
|
-
|
Mar 21
2024
|
Benjamin J. Hindson |
BUY
Grant, award, or other acquisition
|
Direct |
71,083
+16.72%
|
-
|
Mar 21
2024
|
Serge Saxonov Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
88,854
+9.04%
|
-
|
Mar 14
2024
|
Serge Saxonov Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
1,086
-0.13%
|
-
|
Mar 04
2024
|
Serge Saxonov Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,660
-0.55%
|
$205,040
$44.0 P/Share
|
Feb 22
2024
|
Serge Saxonov Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,821
-0.33%
|
$129,766
$46.34 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 297K shares |
---|---|
Exercise of conversion of derivative security | 23.3K shares |
Open market or private sale | 86.7K shares |
---|---|
Bona fide gift | 4.68K shares |